{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-039357","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.189071+00:00","generated_at":"2026-06-11T10:02:54.901146+00:00","sec_items":["2.02","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Catalyst Biosciences provides H1 2023 financials of target Beijing Continent; revenue up 21% YoY","bullets":["BC revenue RMB379.3M, net profit RMB81.2M for H1 2023 vs revenue RMB312.7M, net profit RMB63.9M in H1 2022.","BC main product ETUARY for idiopathic pulmonary fibrosis; gross margin 96% in H1 2023.","BC total assets RMB806.6M, equity RMB707.8M as of June 30, 2023.","Catalyst's acquisition of indirect controlling interest in BC subject to stockholder approval; proxy mailed July 20, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-039357","json":"https://secwatch.observer/filing/0001140361-23-039357.json","markdown":"https://secwatch.observer/filing/0001140361-23-039357.md","text":"https://secwatch.observer/filing/0001140361-23-039357.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123039357/0001140361-23-039357-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123039357/brhc20056996_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T10:02:54.901146+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}